BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA® (Zanubrutinib) in One New Indication, and the First Listing for Pamiparib
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene (NASDAQ:BGNE; HKEX:06160), a global science-driven biotechnology company focused on developing innovative and affordable medicines to...

Court-martial proceedings begin against two Navy officers over INS Brahmaputra capsize
Cabinet grants Agniveers two more years and a wider route into regular forces
Zverev’s No. 1 debut ends in straight sets: what the Musetti loss actually says
SSC CGL answer key 2026 gives candidates a response sheet to audit, not a result to trust
UAE and Oman Battle for Standings Edge in ICC World Cup League 2 Push 






















